- Home
- GALT vs MNOV Comparison
GALT vs MNOV Comparison
Compare GALT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- MNOV
- Stock Information
- Founded
- GALT 2000
- MNOV 2000
- Country
- GALT United States
- MNOV United States
- Employees
- GALT N/A
- MNOV N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- MNOV Health Care
- Exchange
- GALT Nasdaq
- MNOV Nasdaq
- Market Cap
- GALT 86.0M
- MNOV 76.5M
- IPO Year
- GALT N/A
- MNOV 2005
- Fundamental
- Price
- GALT $1.38
- MNOV $1.47
- Analyst Decision
- GALT Hold
- MNOV Strong Buy
- Analyst Count
- GALT 1
- MNOV 1
- Target Price
- GALT N/A
- MNOV $9.00
- AVG Volume (30 Days)
- GALT 177.7K
- MNOV 9.7K
- Earning Date
- GALT 05-19-2025
- MNOV 05-16-2025
- Dividend Yield
- GALT N/A
- MNOV N/A
- EPS Growth
- GALT N/A
- MNOV N/A
- EPS
- GALT N/A
- MNOV N/A
- Revenue
- GALT N/A
- MNOV N/A
- Revenue This Year
- GALT N/A
- MNOV N/A
- Revenue Next Year
- GALT N/A
- MNOV N/A
- P/E Ratio
- GALT N/A
- MNOV N/A
- Revenue Growth
- GALT N/A
- MNOV N/A
- 52 Week Low
- GALT $0.73
- MNOV $1.12
- 52 Week High
- GALT $3.41
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- GALT 49.81
- MNOV 48.15
- Support Level
- GALT $1.26
- MNOV $1.46
- Resistance Level
- GALT $1.63
- MNOV $1.55
- Average True Range (ATR)
- GALT 0.13
- MNOV 0.06
- MACD
- GALT 0.02
- MNOV 0.00
- Stochastic Oscillator
- GALT 37.50
- MNOV 25.00
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.